Last update 07 Jul 2026
Beijing Chigenovo Co., Ltd.

Beijing Chigenovo Co., Ltd.

Startups
| Holding Company|2016|Beijing Shi, China|
www.chinagene.cc

Overview

Basic Info

Introduction
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Tags

Eye Diseases
Other Diseases
Congenital Disorders
AAV based gene therapy
Gene therapy
Gene editing

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Top 5 Drug TypeCount
AAV based gene therapy3
Gene therapy2
Gene editing2
Fusion protein1
Top 5 TargetCount
ABCA4(ATP binding cassette subfamily A member 4)1
RP4(Rhodopsin)1
CYP4V2(cytochrome P450 family 4 subfamily V member 2)1

Related

8
Drugs associated with Beijing Chigenovo Co., Ltd.
ZVS-101e
Target
CYP4V2
Mechanism
CYP4V2 replacements [+1]
Active Org.
Beijing Chigenovo Co., Ltd.Beijing Chigenovo Co., Ltd.
Originator Org.
Beijing Chigenovo Co., Ltd.Beijing Chigenovo Co., Ltd.
Active Indication
Bietti Crystalline Dystrophy
Inactive Indication
Retinal Degeneration
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
ZVS-203e
Target
RP4
Mechanism
RHO gene transference
Active Org.
Beijing Chigenovo Co., Ltd.Beijing Chigenovo Co., Ltd.
Originator Org.
Beijing Chigenovo Co., Ltd.Beijing Chigenovo Co., Ltd.
Active Indication
Retinitis Pigmentosa
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
ZVS-106e
Target-
Mechanism-
Active Org.
Beijing Chigenovo Co., Ltd.Beijing Chigenovo Co., Ltd.
 [+1]
Originator Org.
Beijing Chigenovo Co., Ltd.Beijing Chigenovo Co., Ltd.
Active Indication
Hereditary retinal dystrophy [+1]
Inactive Indication-
Drug Highest PhaseEarly Phase 1
First Approval Ctry. / Loc.-
First Approval Date-
7
Clinical Trials associated with Beijing Chigenovo Co., Ltd.
NCT07653971
/ Not yet recruitingNot Applicable
Clinical Translation and Application Protocol for ZVS101e in the Gene Therapy of Bietti Crystalline Corneoretinal Dystrophy
NCT07307469
/ Enrolling by invitationNot Applicable
Compassionate Administration of ZVS101e for Extended Treatment
NCT07241169
/ RecruitingEarly Phase 1IIT
A Preliminary Clinical Study on the Safety and Efficacy of the Gene Replacement Drug ZVS106e in the Treatment of Hereditary Retinal Degeneration (IRDs) Caused by ABCA4 Biallelic Mutations
100 Clinical Results associated with Beijing Chigenovo Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Beijing Chigenovo Co., Ltd.
Login to view more data
100 Deals associated with Beijing Chigenovo Co., Ltd.
Login to view more data
100 Translational Medicine associated with Beijing Chigenovo Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
3
3
Preclinical
Phase 2
1
1
Phase 3
Other
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ZVS-101e
 ( CYP4V2 )		Bietti Crystalline Dystrophy
More
Phase 3
ZVS-203e
 ( RP4 )		Retinitis Pigmentosa
More
Phase 1/2
ZVC-105e
Retinitis Pigmentosa
More
Preclinical
ZVS-204e
Retinitis Pigmentosa
More
Preclinical
ZVS-106e
Stargardt Disease
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free